Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019
https://doi.org/10.21292/2075-1230-2020-98-1-5-15
Abstract
The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.
Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.
Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.
About the Authors
D. A. Ivanova
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Diana A. Ivanova – Doctor of Medical Sciences, Academic Secretary.
10, Stromynka St., Moscow, 107014
Phone/Fax: +7 (499) 269-14-10, 8 (495) 964-86-37.
S. E. Borisov
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Sergey E. Borisov – Doctor of Medical Sciences, Professor, Deputy Director for Research.
10, Stromynka St., Moscow, 107014
Phone/Fax: +7 (499) 268-50-10, +7 (499) 785-20-82.
O. V. Rodina
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Olga V. Rodina – Head of Tuberculosis Lung Department no. 1 of Clinic no. 2.
10, Stromynka St., Moscow, 107014
A. V. Filippov
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Aleksey V. Filippov – Senior Researcher of Research Clinical Department.
10, Stromynka St., Moscow, 107014
T. N. Ivanushkina
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Taisia N. Ivanushkina – Head of Tuberculosis Lung Department no. 2 of Clinic no. 1.
10, Stromynka St., Moscow, 107014
N. V. Litvinova
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Natalia V. Litvinova – Leading Researcher of Research Clinical Department.
10, Stromynka St., Moscow, 107014
References
1. Borisov S.E., Filippov А.V., Ivanova D.А., Ivanushkina T.N., Litvinova N.V., Garmash Yu.Yu. Efficacy and safety of chemotherapy regimens containing bedaquiline in respiratory tuberculosis patients: immediate and final results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 5, pp. 28-42. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-5-28-40.
2. Vasilyeva I.А., Belilovsky E.M., Borisov S.E., Sterlikov S.А. Multiple drug resistant tuberculosis in the world and Russian Federation. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 11, pp. 5-17. (In Russ.)
3. Opredelenie stepeni dostovernosti prichinno-sledstvennoy svyazi «neblagopriyatnaya pobochnaya reaktsiya – lekarstvennoe sredstvo» (klassifikatsiya i metody): metodicheskie rekomendatsii. [Defining the degree of causal relationships between an adverse event and the drug (classification and methods): guidelines]. Federalnaya Sluzhba Po Nadzoru V Sfere Zdravookhraneniya I Sotsialnogo Razvitiya Publ., Moscow, 2008, Available: http://pandia.ru/text/78/557/9463.php. (Accessed 29.03.2018).
4. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis., 2012, vol. 16, no. 4, pp. 447-454.
5. Diacon A.H., Pym A., Grobusch M.P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med., 2014, vol. 371, no. 8, pp. 723-732.
6. Division of Microbiology and Infection Diseases (DMID) adult toxicity table / Microbiology and Infectious Diseases Clinical Research Policies, Guidance, and Tools. National Institute of Allergy and Infectious Diseases, Bethesda, 2007. Available: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.pdf. (Available: 09.07.2013).
7. Global Tuberculosis Report 2018. WHO/CDS/TB/2018.20. World Health Organization, 2018, pp. 95-96.
8. Harari S. Randomised controlled trials and real-life studies: two answers for one question. Eur. Respir. Rev., 2018, vol. 27: 180080.
9. Mbuagbaw L., Guglielmetti L., Hewison C. et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg. Infect. Dis., 2019, vol. 25, no. 5, pp. 936-943. https://dx.doi.org/10.3201/eid2505.181823.
10. Merid M.W., Gezie L.D., Kassa G.M. et al. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. BMC Infect Dis., 2019, vol. 19, pp. 286. https://doi.org/10.1186/s12879-019-3919-1.
11. Perrin F.M., Woodward N., Phillips P.P. et al. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis., 2010, vol. 14, no. 12, pp. 1596-1602.
12. Singh B., Cocker D., Ryan H., Sloan D.J. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev., 2019, vol. 3, no. 3, CD012836.
13. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva, WHO, 2013, 57 p.
14. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO/CDS/TB/2019.3. Geneva, World Health Organization, 2019. Available: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/ (Accessed 29.03.2019).
15. Wu S., Zhang Y., Sun F. et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am. J. Ther., 2013, Available: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0061918/ (Accessed 29.03.2019).
16. Yamaguti V., Rijo R., Crepaldi N., Ruffino-Netto A., Carvalho I., Alves D. Charlson Comorbidities Index importance evaluation as a predictor to tuberculosis treatments outcome in the state of São Paulo, Brazil. Procedia Computer Science, 2018, vol. 138, pp. 258-263. https://doi.org/10.1016/j.procs.2018.10.037.
Review
For citations:
Ivanova D.A., Borisov S.E., Rodina O.V., Filippov A.V., Ivanushkina T.N., Litvinova N.V. Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. Tuberculosis and Lung Diseases. 2020;98(1):5-15. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-1-5-15
Views:
1565
Email this article 